BackImmunityBio Overview

ImmunityBio Current Cash

Track ImmunityBio's current cash ($76M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$75.67M
↓ 45.03% YoYΔ $-61.99M vs prior year quarter

Peer trimmed avg / median

Loading

ImmunityBio Current Cash History

Loading

ImmunityBio vs. peers: Current Cash Comparison

Loading

ImmunityBio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ImmunityBio (IBRX) FAQ

ImmunityBio (IBRX) currently reports a current cash of $76M as of June 2026. That compares with $140M in the prior-year period — down 45.0% year over year. Use the charts on this page to explore ImmunityBio's current cash history and peer comparisons.

ImmunityBio's current cash decreased from $140M to $76M — a 45.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunityBio reported $76M in current cash as of June 2026. That compares with $140M in the prior-year period — down 45.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $76M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunityBio, and consider following IBRX for alerts when major investors trade the stock.

ImmunityBio is classified in the Healthcare sector. On current cash, it currently shows $76M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBRX with unrelated industries.